BioLineRx Ltd. filings document the regulatory record of a foreign private issuer focused on oncology and rare-disease drug development. Recent Form 6-K reports include financial results, interim consolidated financial statements, operating and financial reviews, and press-release exhibits incorporated by reference into effective Securities Act registration statements.
The filings also record company-specific matters such as the GLIX1 collaboration and joint-venture agreements with Hemispherian, GLIX1 patent and clinical-development disclosures, motixafortide and APHEXDA commercial context, and a final arbitration award involving the motixafortide in-licensing agreement. These disclosures frame BioLineRx's business updates, capital commitments, intellectual-property position, legal contingencies, and governance authorization as a Nasdaq- and TASE-listed issuer.
BioLineRx Ltd. registered for resale up to 2,023,382 ADSs issuable upon exercise of warrants held by Armistice Capital, LLC. Each ADS represents 600 ordinary shares, or up to 1,214,029,200 ordinary shares. The selling shareholder may sell all, some or none through market, negotiated or other transactions.
BioLineRx receives no proceeds from ADS resales; it may receive proceeds if warrants are exercised for cash. Full cash exercise of all warrants would produce $5.6 million; the warrants also may be exercised cashlessly in certain circumstances. Their exercise price is $2.78 per ADS, with a five-year term from issuance and an ownership limit of 4.99%, or 9.99% at the holder’s election. BioLineRx will pay estimated registration expenses of $30,000. The 2025 audit report incorporated by reference contains an explanatory paragraph related to BioLineRx’s ability to continue as a going concern.
BioLineRx Ltd. filed to register for resale up to 2,023,382 ADSs, each representing 600 ordinary shares, issuable upon exercise of warrants held by Armistice Capital, LLC. The selling shareholder may not sell until the registration statement becomes effective. The ADSs represent up to 1,214,029,200 ordinary shares; BioLineRx reported 2,986,929,790 ordinary shares outstanding as of September 24, 2026.
BioLineRx receives no proceeds from resales. It may receive proceeds only if the warrants are exercised for cash; full cash exercise would produce $5.6 million, intended for research and development, working capital and general corporate purposes. The warrants have a $2.78 per ADS exercise price, may be exercised cashlessly in certain circumstances, and have a 4.99% beneficial-ownership limit, or 9.99% at the holder’s election. BioLineRx states that resales could adversely affect the ADS market price. Its incorporated 2025 financial statements include an auditor’s explanatory paragraph concerning its ability to continue as a going concern.
BioLineRx Ltd. (BLRX) said shareholders approved, by the requisite majority under the Israel Companies Law and the company’s articles of association, each proposal set forth in the proxy statement for its September 23, 2026 annual general meeting. The report is incorporated by reference into all effective registration statements BioLineRx filed under the Securities Act of 1933.
BioLineRx Ltd. (BLRX) reports that two scientific abstracts on its lead asset GLIX1, developed with Hemispherian AS, have been accepted for presentation at the EANO 2026 neuro-oncology conference, including a mini-oral highlighting preclinical efficacy in orthotopic glioblastoma models and an e-poster detailing the ongoing Phase 1/2a trial design.
Preclinical data show that GLIX1, an oral TET2 activator targeting the DNA damage response, achieved brain exposure at 68–85% of plasma levels in mice and produced dose-dependent tumor growth inhibition and survival benefit across two orthotopic GBM xenograft models at all tested doses. These findings supported initiation of a first-in-human, open-label, multicenter Phase 1/2a study in recurrent or progressive high-grade glioma using a BOIN dose-escalation design across up to 5 dose levels in up to 30 patients, with primary endpoints focused on safety, tolerability, and determination of MTD/RP2D.
BioLineRx Ltd. (BLRX), an Israel-incorporated biotechnology company, filed a Form D for an exempt offering under Rule 506(b) of Regulation D. The notice covers a completed $3,750,000 offering of options/warrants and the securities issuable upon their exercise, with no remaining amount to be sold.
The securities were issued together with a registered direct offering of 480,696 American depositary shares (ADSs) and 868,225 pre-funded warrants, plus unregistered warrants to purchase 2,023,382 ADSs. BioLineRx intends to use the net proceeds for research and development activities, working capital, and general corporate purposes. Chardan Capital Markets LLC is entitled to a 1.0% management fee on gross proceeds and $50,000 for accountable expenses, with no sales commissions or finder’s fees reported.
BioLineRx Ltd. (BLRX) is conducting a takedown under its Form F-3 shelf to raise capital through a primary offering of 480,696 ADSs at $2.78 per ADS and pre-funded warrants to purchase up to 868,225 ADSs at $2.7799 per pre-funded warrant, each ADS representing 600 ordinary shares. The pre-funded warrants have a $0.0001 exercise price per ADS, are immediately exercisable and have no expiration, subject to a 4.99% (or 9.99%) beneficial ownership limitation.
Concurrently, in a private placement, the company is issuing warrants to purchase up to 2,023,382 ADSs at an exercise price of $2.78 per ADS, exercisable immediately for five years. Gross proceeds from the registered component are $3.75 million, with proceeds before expenses of $3.45 million after placement-agent cash fees; net proceeds are estimated at approximately $3.3 million, to be used for research and development, working capital and general corporate purposes.
Ordinary shares outstanding will be 2,909,394,790 after the offering, assuming no exercise of the new warrants. BioLineRx highlights significant dilution risk, volatility in its ADS price, dependence on oncology programs such as GLIX1 and motixafortide/APHEXDA, substantial geopolitical risk due to its Israeli base, and potential Nasdaq listing risk including a proposed $5.0 million market-value-of-listed-securities standard.
BioLineRx Ltd. (BLRX) entered into agreements for a registered direct offering of 480,696 ADSs and Pre-funded Warrants to purchase up to 868,225 ADSs, together with a concurrent private placement of unregistered Warrants to purchase up to 2,023,382 ADSs.
The purchase price is $2.78 per ADS and accompanying Warrant and $2.7799 per Pre-funded Warrant and accompanying Warrant; Pre-funded Warrants are immediately exercisable at $0.001 per ADS and do not expire, while the Warrants have a five-year term and a $2.78 exercise price. Aggregate gross proceeds (assuming full exercise of Pre-funded Warrants and no exercise of the Warrants) are expected to be about $3.75 million before fees. BioLineRx will pay the placement agent a 7.0% cash fee, a 1.0% management fee and up to $50,000 of expenses, and plans to use net proceeds for research and development, working capital and general corporate purposes. The company agreed to 120-day restrictions on variable rate transactions and 60-day standstill restrictions and amended existing warrants for 277,273 ADSs to cut the exercise price to $2.78 and extend the term to August 31, 2031.
BioLineRx Ltd. (BLRX) reported unaudited results for the quarter and six months ended June 30, 2026 and detailed progress on its oncology pipeline. Lead asset GLIX1, a first-in-class oral DNA damage response modulator for glioblastoma and other solid tumors, is in an ongoing Phase 1/2a trial, with the second of five planned cohorts dosing and the third expected to start in September 2026. New preclinical data showed robust antitumor activity in temozolomide-resistant GBM models and strong synergy with PARP inhibitors in homologous-recombination–proficient ovarian cancer, supporting plans to add an ovarian cancer arm in the Phase 2a expansion.
Royalty revenues were $294k for Q2 2026 and $771k for the first half of 2026, while the company recorded an operating loss of $3.6m in Q2 and a net loss of $6.9m for the first half. Cash and cash equivalents plus short-term deposits totaled $13.1m at June 30, 2026. Management believes existing resources fund operations into the first half of 2027 but discloses a material uncertainty that may cast significant doubt on its ability to continue as a going concern.
Subsequent to quarter-end, BioLineRx agreed to a registered direct offering of 1,348,921 ADSs or pre-funded warrants at $2.78 per ADS, plus 2,023,382 five-year warrants at the same exercise price, for $3.75m in gross proceeds, and amended 277,273 existing warrants to reduce the exercise price and extend maturity.
BioLineRx Ltd. (BLRX) entered into a definitive agreement for a registered direct offering of 1,348,921 American Depositary Shares (ADSs) or ADS equivalents at $2.78 per ADS, together with a concurrent private placement of warrants to purchase up to 2,023,382 ADSs at the same price. The warrants carry an exercise price of $2.78 per ADS and a term of five years from issuance, with closing expected on or about August 31, 2026, subject to customary conditions. Aggregate gross proceeds are expected to be $3.75 million, to be used for research and development, working capital and general corporate purposes. Each ADS represents 600 ordinary shares of BioLineRx. In connection with this financing, BioLineRx reduced the maximum aggregate offering amount under its At-the-Market facility to $0 from $4,870,000 and amended 277,273 existing warrants held by the investor, reducing their exercise price to $2.78 per ADS and extending the expiration date to August 31, 2031.